Biochemical and biophysical characterization of four EphB kinase domains reveals contrasting thermodynamic, kinetic and inhibition profiles

Ross C. OVERMAN*1, Judit E. DEBRECZENI*, Caroline M. TRUMAN*, Mark S. McALISTER* and Teresa K. ATTWOOD†

*AstraZeneca PLC, Alderley Park, Cheshire, SK10 4TG, U.K., and †Faculty of Life Sciences and School of Computer Science, The University of Manchester, Oxford Road, Manchester M13 9PL, U.K.

Synopsis
The Eph (erythropoietin-producing hepatocellular carcinoma) B receptors are important in a variety of cellular processes through their roles in cell-to-cell contact and signalling; their up-regulation and down-regulation has been shown to have implications in a variety of cancers. A greater understanding of the similarities and differences within this small, highly conserved family of tyrosine kinases will be essential to the identification of effective therapeutic opportunities for disease intervention. In this study, we have developed a route to production of multi-milligram quantities of highly purified, homogeneous, recombinant protein for the kinase domain of these human receptors in Escherichia coli. Analyses of these isolated catalytic fragments have revealed stark contrasts in their amenability to recombinant expression and their physical properties: e.g., a >16 °C variance in thermal stability, a 3-fold difference in catalytic activity and disparities in their inhibitor binding profiles. We find EphB3 to be an outlier in terms of both its intrinsic stability, and more importantly its ligand-binding properties. Our findings have led us to speculate about both their biological significance and potential routes for generating EphB isozyme-selective small-molecule inhibitors. Our comprehensive methodologies provide a template for similar in-depth studies of other kinase superfamily members.

Key words: EphB1, EphB2, EphB3, EphB4, kinase inhibition, protein stability

INTRODUCTION

The Eph (erythropoietin-producing hepatocellular carcinoma) B receptors (EC 2.7.10.1) constitute one-third of the ephrin RTK (receptor tyrosine kinase) subfamily; they are type I transmembrane proteins, and form the largest grouping within the tyrosine kinase family [1]. In warm-blooded vertebrates, the Eph subfamily consists of 15 members [2], 14 of which are present in humans [3]: namely, EphA1–A8, A10, EphB1–B4 and B6. The EphA and EphB receptors recognize and interact with their respective ligands, the ephrins, which are found on the surface of neighbouring cells, through highly selective, nanomolar affinity interactions [4]. The interactions between ephrins and Eph receptors on adjacent cells give rise to cell-to-cell contacts and bi-directional intracellular signalling cascades that mediate cellular repulsion, adhesion and migration [5]. Eph receptors are also implicated in extracellular matrix attachment [6], cell boundary formation [7] and tissue morphogenesis [8], including blood vessel maturation within the cardiovascular system [9] and axonal path finding within the nervous system [10,11].

The EphB receptors and their ligands have been implicated in the progression of a variety of human cancers, a role that appears to be complex and often conflicting, depending on the type of cancer and stage of progression [12]. For example, EphB2 kinase domain inactivating mutations have been found in prostate cancer cell lines, implicating a role for EphB2 as a tumour suppressor.
EphB2 has also been shown to promote cell proliferation in intestinal epithelia through its tyrosine kinase activity [14], while conversely inhibiting invasive growth by a kinase-independent mechanism [15]. EphB4 epithelial up-regulation has been observed in late-stage ovarian cancer [16], while being down-regulated, and having tumour suppressor activities, in intestinal cancers [17]. EphB3 has been shown to suppress growth of a human colon cancer cell by strengthening cell–cell contacts [18], and its increased activity can suppress non-small-cell lung-cancer metastasis [19]. Conversely, elevated levels of EphB3 have been shown to have a role in the failure of contact inhibition of locomotion exhibited by certain metastatic prostate cancer cell lines overexpressing this receptor [20], an observation that results in a more invasive phenotype. The reduced expression of EphB1 has been linked with invasion and metastasis in both colorectal [21] and gastric carcinomas [22], while blocking EphB1 forward signalling may have a clinical benefit in relieving bone cancer pain [23]. The complexity and divergent nature of the many examples of Eph receptor up- and down-regulation in so many different areas of oncology has resulted in a variety of novel anti-cancer therapies; those currently under investigation include antibodies, peptides and small-molecule kinase inhibitors [24].

The development of potent and selective small molecules to modulate the activity of the EphB receptors could aid deconvolution of the complex roles of these receptors in cancer disease models, or indeed serve as therapeutic agents. Hence, this study focuses on generating a clearer understanding of the structure–function relationship of the catalytic domains of the closely related EphB receptors (EphB1–4), excluding the more divergent EphB4, in order to identify and validate its regulatory mechanism [25]. In this study, we describe Escherichia coli-based methods for producing and isolating multi-milligram quantities of active kinase domain for testing disparities between these important enzymes in terms of inhibitor binding profiles.

**EXPERIMENTAL**

All chemicals were obtained from Sigma unless otherwise stated.

**Molecular biology**

Catalytic domain genes for the four EphB tyrosine kinases were synthesized in vitro by GENEART AG (Life Technologies); EphB1 residues 602–896 (UniProtKB/Swiss-Prot: EPHB1_HUMAN, P54762), EphB2 residues 604–898 (UniProt/Swiss-Prot: EPHB2_HUMAN, P29323), EphB3 residues 616–910 (UniProtKB/Swiss-Prot: EPHB3_HUMAN, P54753) and EphB4 residues 598–892 (UniProtKB/Swiss-Prot: EPHB4_HUMAN, P54760). An EphB3 C171G mutant was also produced as a synthetic gene, created as a variant of the wild-type sequence. All sequences were codon-optimized for*E. coli* expression. Bacterial expression vectors were generated using the Gateway® Cloning System (Life Technologies); synthesized genes were sub-cloned into the Gateway®-adapted pT7#3.3 N6His*E. coli* expression vector [26]. The resulting expression vectors contained an N-terminal His6 tag to facilitate purification, and a TEV (tobacco etch virus) cleavage site upstream of each EphB catalytic domain: MHHH-HHHGSTSLYKAGSENLYFPQGSS. An additional expression vector (pRSF1-PTP1B) for phosphatase co-expression was also constructed. pRSF1-PTP1B contained a single copy of the human PTP1B (protein tyrosine phosphatase 1Beta) protein (UniProtKB/Swiss-Prot: PTN1_HUMAN, P18031, residues 1–288) inserted into the pRSF-1b plasmid (EMD Chemical, Merck KGaA).

**Protein expression and purification**

Kinetik expression vectors were transformed into*E. coli* BL21 Star™ (DE3) cells (Life Technologies) in the presence or absence of pRSF1-PTP1B and/or the GroES–GroEL containing vector pGro7 (Takara Bio). Each of the three vector types contained a different antibiotic selection marker and origin of replication, enabling all three to be maintained within the same bacterial cell at any one time (pT7#3.3: Te†, CoEl origin, T7 promoter; pRSF-1b: Kan†, RSFI origin, T7 promoter; pGro7: Cam†, pACYC origin, arabinose promoter).

Cells were cultured at 37 °C, 220 rpm from a starting *D*~600~ (attenuance at 600 nM) of 0.075 in LB (Luria–Bertani) broth plus antibiotics. For pGro7-containing cultures, the addition of L- (+)–arabinose to a final concentration of 1 g/l was required to induce chaperone expression. At an average *D*~600~ of 0.35, the temperature was reduced to 18 °C and expression of recombinant EphB proteins (and PTP1B, where present) was induced with 0.1 nM IPTG (isopropyl β-D-thiogalactopyranoside) at an average *D*~600~ of ~0.80 for 20 h. Cells were harvested by centrifugation at 12 000 g.

Cells were re-suspended in base buffer (40 mM Hepes, 500 mM NaCl and 1 mM TCEP [tris-(2-carboxyethyl)phosphine], pH 8.0) supplemented with 10 nM imidazole, 1 mg/ml hen egg white lysozyme (Sigma), 0.1 μg/ml Benzonase® Nuclease HC (Novagen) and EDTA-free Complete™ (protease inhibitor cocktail tablets; Roche). Cells were lysed using a 2.2 kW TS series cell lysis system (Constant Systems) at 25 kpsi. Insoluble material was removed by centrifugation at 35 000 g for 60 min. Clarified supernatants were applied to 3 ml Ni-NTA (Ni 2+–nitrilotriacetic acid) Superflow resin columns (Qiagen). The columns were washed with 10–50 CVs (column volumes) of base buffer supplemented with 25 mM imidazole. Bound proteins were eluted with base buffer supplemented with 0.5 M imidazole. Elution fractions were pooled and dialysed against dialysis buffer (40 M Hepes, 0.5 M NaCl, 5 mM imidazole and 1 mM TCEP, pH 8.0) for 16 h at 4 °C in the presence of His6-TEV protease (Life Technologies).
Characterization of four EphB kinase domains

Determination of phosphorylation status

For detection of tyrosine phosphorylation of proteins from *E. coli* preparations, 0.5 μg affinity-purified kinase was analysed by Western blotting using 1:2000 anti-phosphotyrosine mouse monoclonal antibody (pY100; NEB Cell Signalling) with 1:1000 HRP (horseradish peroxidase)-conjugated rabbit-anti-mouse secondary antibody (Sigma) and detection using Supersignal West Femto ECL reagent (Thermo Scientific Pierce).

To obtain quantifiable phosphorylation data, EphB kinase samples at 1 mg/ml in crystallization buffer were loaded on to a Micromass LCT ES-TOF (liquid chromatography electrospray ionization time-of-flight) mass spectrometer, using a Waters 2790 HPLC as the inlet. 15 μg protein was injected for each measurement on to a Phenomenex Jupiter 5 μm C5 300A column, 150×2.0 mm. Protein was eluted using a fast gradient [0–90% B over 45 min at 120 ml/min; eluent A was aqueous 0.1 % TFA (trifluoroacetic acid), eluent B was 90 % acetonitrile 0.1 % TFA]. Electrospray mass spectrometer data were collected between 12 and 25 min post injection, and deconvoluted using MaxEnt1 software (Waters). Theoretical protein masses were calculated using the MassLynx™ software (Waters).

Thermal unfolding analyses

Thermal unfolding measurements were conducted by CD using a Jasco J-810 Spectropolarimeter with Peltier-controller. Proteins were rapidly defrosted and extensively dialysed against 50 mM sodium phosphate and 1 mM TCEP, pH 7.4. Protein concentrations were determined by attenuation at 280 nm using a Cary 300 Bio UV-Vis spectrophotometer and predicted molar absorption coefficient (ε). All CD measurements were conducted with 10 μM protein in a 1 mm path length non-dentountable cuvette. Initial wavelength scans were performed at 20°C from 260 to 195 nm, with continuous scanning at 20 nm/min with a 1 nm bandwidth, 0.1 nm data pitch and a response of 2 s with standard sensitivity. Unfolding was monitored at 222 nm (α-helical response), with temperature scan from 20 to 80°C and a 1°C data pitch with a delay time of 60 s. The chosen response time was 4 s, with a 1 nm bandwidth and standard sensitivity. Three scans were performed for each protein. The primary data points (CD [mdeg] against temperature) were extracted and analysed within the Prism analysis package (version 5, GraphPad). The unfolding curves normalized and fitted to a six-parameter unfolding equation (Equation 1), adapted from [27] to obtain the $T_m$ of unfolding and the $\Delta_H^{app}(T_m)$, the van’t Hoff enthalpy.

$$Y_{obs} = \frac{\exp[-\Delta H_m\left(1 - \frac{T}{T_m}\right)/RT]\left(a_u + b_uT\right) + \left(a_n + b_nT\right)}{1 + \exp[-\Delta H_m\left(1 - \frac{T}{T_m}\right)/RT]}$$  

where $T$ is the temperature, $T_m$ is the midpoint of the unfolding transition, $\Delta H_m$ is the change in enthalpy at the transition temperature ($T_m$), $R$ is the gas constant, $a_u$ and $b_u$ define the pre-transition and $a_n$ and $b_n$ define the post-transition regions of the curve. Two main parameters were extracted from this calculation: the $T_m$ of unfolding and the $\Delta H_m$, which is $\Delta H(T)$ or $\Delta H^{app}(T_m)$, the van’t Hoff enthalpy.

Solution-stability analyses

Chaotrope-induced protein unfolding was monitored by the change in intrinsic tryptophan fluorescence using Tecan XFLUOR4SAFIRE II plate-based scanning fluorimeter, with Greiner Black flat-bottom polystyrene 96- or 384-well plates. Two stock buffers were prepared from which a range of GdnHCl (guanidine hydrochloride) concentrations could be produced: fluorescence buffer A – 20 mM Hepes and 50 mM NaCl, pH 7.4; fluorescence buffer B – 20 mM Hepes, 50 mM NaCl and 6 M GdnHCl, pH 7.4. The final protein concentration used per well was 3 μM in a final volume of 15 μl (384-well) or 150 μl (96-well). Emission scans were conducted with an $\lambda_{em}$ of 295 nm and $\lambda_{ex}$ from 300 to 450 nm in 1 nm steps. Excitation and emission bandwidth was 5 nm, with a gain of 75 and integration time of 40 μs, lag time of 0 μs and temperature of 25°C ± 0.5°C. Peak tyrosine emission fluorescence for the folded proteins was judged to be 345 nm. Unfolding measurements were conducted with an $\lambda_{ex}$ of 295 nm, $\lambda_{em}$ of 345 nm and excitation and emission bandwidth was 2.5 nm, with a gain of 152 and integration time of 40 μs, lag time of 0 μs and temperature of 25°C ± 0.5°C. Unfolding curves were fitted to both two- and three-state unfolding models [28,29] using Prism (version 5; GraphPad) and Akaike information criteria to determine the probability of fit to the best unfolding model.

Steady-state enzyme kinetics and small-molecule compound screening

Kinetic assays were based on *in vitro* phosphorylation of a generic tyrosine kinase substrate poly-(Glu-Tyr) (4:1, 20000–50000 Da; Sigma) in a stopped reaction format, using the ADP-Glo™ luminescent kinase assay kit (Promega). Reactions were performed in low-volume, flat-bottom white polystyrene 384-well plates in a total reaction volume of 4 μl; 2 μl/well of enzyme solution (50 nM EphB enzyme, 10 mM MgCl2, 100 mM Hepes, pH 7.5, 1 mM DTT and 0.02 % v/v Brij-35) was mixed with 2 μl/well of ATP and substrate for a total of 140 min following the addition.
of enzyme, with time points at 0, 20, 40, 60, 80, 100, 120 and 140 min. The reactions were stopped by the addition of 4 μl of ADP-GloTM Reagent 1 (Promega) with 40 min incubation, followed by 8 μl of kinase detection reagent for a further 60 min in the dark, before reading plates using a Pherastar plate reader (BMG Labtech) with a luminescence filter, at a read height of 14 mm and a 0.5 s integration time. All incubations were carried out at 21 °C. The $K_m$ for ATP was measured using a concentration range of 0–5 mM ATP at a fixed poly-(Glu:Tyr) concentration of 10 mg/ml. The $K_m$ for poly-(Glu:Tyr) was measured using a concentration range of 0–10 mg/ml poly-(Glu:Tyr) at a fixed ATP concentration of 5 mM. Enzyme and substrate additions were made using a BioRAPTR (Beckman Coulter). Values for $K_m$, $V_{max}$ and $k_{cat}$ were calculated using Prism analysis software (version 5; GraphPad) by Michaelis–Menten nonlinear regression analysis.

For the compound response testing, ATP and poly-(Glu:Tyr) were used at $K_m$ for each kinase (Table 1) and the kinase reaction was incubated for 40 min. The compound concentration range was across 12 points. Compounds were dosed into assay-ready plates using 11 half-log intervals, followed by the 12th point, which was a whole log interval from the 11th (Echo 555; Labcyte). Each well was backfilled with the required volume up to 40 nl of 100% DMSO to ensure a final 1% DMSO concentration in the assay. Each plate contained at least 11 randomly distributed maximum and minimum controls. CMPD3 (compound 3, see Figure 4) was used to inhibit EphB constructs for the minimum control, with the exception of EphB1 and EphB3, where CMPD3 was replaced with an artificial minimum from full inhibition compounds from dose-response curves. For the maximum control, 40 nl pure DMSO was added to wells.

**Determinant of IC$_{50}$**

Using the maximum and minimum control wells as references for the 0% and 100% enzyme inhibition points, it was possible to calculate the effect of each compound on the kinase activity of each of the EphB constructs. For enzyme inhibition, nonlinear curve fit analysis within OriginLabTM software was used to fit dose-response curves, and was used to estimate the concentration of compound required to reduce the enzyme activity to 50%.

### RESULTS

**Recombinant kinase production**

The EphB kinase domain construct boundaries chosen for this study were based on those used previously for EphB4 structure determination [30], and differ from those used for previous structural studies of EphB2 [31,32], as they do not contain the auto-inhibitory juxtamembrane region (Supplementary Figure S1 and Supplementary Table S1 available at http://www.bioscirep.org/bsr/033/bsr033e040add.htm). The recombinant *E. coli* expression of the four kinases was examined in the presence and absence of human PTP1B and/or the recombinant GroES–GroEL chaperone complex. The variation in soluble expression and phosphorylation state was marked between the four kinases as can be seen in Figure 1. EphB2 was found to be non-transformable, and therefore presumably toxic to the host *E. coli* strain used. This toxicity could be overcome through co-expression with PTP1B, resulting in high levels of soluble, purifiable material. EphB1 and EphB3 were both found to overexpress in the soluble fraction to >3 mg/l, despite being highly heterogeneously phosphorylated (Figure 1 and Supplementary Table S2 available at http://www.bioscirep.org/bsr/033/bsr033e040add.htm). For EphB4, the purifiable soluble expression level in the absence of GroES–GroEL was almost undetectable by SDS/PAGE (<0.1 mg/l), but was partially rescued by co-expression with GroEL/GroES, albeit at levels much lower than the other three kinases (Figure 1). EphB4, like EphB1 and 3, was also phosphorylated, with an average of two or three phosphorylations per molecule (Supplementary Table S2), all of which were removed through PTP1B co-expression. Using PTP1B (and GroES/GroEL, where required), each of the four kinase domains

### Table 1 Steady-state kinetic properties of the EphB enzymes

| Enzyme | $K_m$ ATP (μM) | $K_m$ poly(glutamic acid:tyrosine) (μg/ml) | $k_{cat}$ (s$^{-1}$) | $V_{max}$ (nmol/min per mg) |
|--------|----------------|------------------------------------------|---------------------|--------------------------|
| EphB1  | 555 ± 36       | 1137 ± 125                               | 0.80 ± 0.02         | 1415 ± 30                |
| EphB2  | 751 ± 60       | 1601 ± 190                               | 1.11 ± 0.04         | 1802 ± 67                |
| EphB3  | 506 ± 48       | 943 ± 91                                 | 0.43 ± 0.01         | 764 ± 23                 |
| EphB4  | 497 ± 39       | 1001 ± 122                               | 0.51 ± 0.01         | 779 ± 21                 |
| EphB3 C717G | 659 ± 67       | 1458 ± 177                               | 0.86 ± 0.03         | 1533 ± 46                |
Characterization of four EphB kinase domains

Table 2  Thermodynamic parameters obtained from thermal and chaotrope unfolding

| Enzyme | $T_m$ (°C) | $\Delta H (\text{kJ/mol})$ | Two-state probability (%) | Three-state probability (%) |
|--------|------------|----------------|--------------------------|---------------------------|
| EphB1  | 59.7 ± 0.2 | 156.6 ± 14.3 | 1.22                     | 98.78                     |
| EphB2  | 53.9 ± 0.2 | 154.2 ± 16.5 | <0.01                    | >99.99                    |
| EphB3  | 45.0 ± 0.1 | 106.2 ± 3.7  | <0.01                    | >99.99                    |
| EphB4  | 42.8 ± 0.2 | 129.3 ± 10.7 | <0.01                    | >99.99                    |

Thermal stability

To investigate whether observed differences in soluble, recombinant expression levels in *E. coli* could be attributed to differences in stability between the isolated kinase domains, thermal unfolding events for each of the four kinase domains were studied using CD spectroscopy. Far UV wavelength scans were performed in phosphate buffer at physiological pH, and demonstrated very similar secondary structure profiles, as would be expected given the level of sequence and structural identity between the two domains (Supplementary Figure S2 available at http://www.bioscierep.org/bsr/033/bsr033e040add.htm).

Chaotropic unfolding

In an attempt to follow the unfolding events of each of the four kinases in greater detail, chaotrope-induced unfolding was
performed. Internal tryptophan fluorescence of the four kinases was monitored at 345 nm in the presence of increasing GdnHCl concentration (Figure 3). Using this technique, a similar pattern of stability was observed to that of thermal unfolding. EphB1 appeared to tolerate a higher concentration of GdnHCl than the other enzymes before beginning to unfold. EphB2 appeared to start unfolding at a lower GdnHCl concentration, while EphB3 and EphB4 were both markedly less tolerant to chaotrope concentration. At a GdnHCl concentration of 3 M, a stable fluorescence minimum for all four kinase domains was reached, indicating complete unfolding. Each of the four proteins appears to fit more closely to a three-state unfolding model than a two-state model (Table 2), with evidence of a partially stable intermediate unfolding state at about 2 M GdnHCl, which appears more pronounced in EphB3 and EphB4, indicating a stable core common to each of the kinases. The most striking observation between the unfolding curves of the four proteins is the apparently ‘unfolded’ state observed at \( \sim 1 \) M GuHCl with EphB3: at this point, the tryptophan emission signal almost disappears and then reappears again at 1.5 M GuHCl.

**Kinetic profiling of the EphB kinase domains**

An in vitro peptide phosphorylation assay was employed to investigate the intrinsic activity of each of the four isolated EphB catalytic domains. The unphosphorylated kinases were incubated with the generic tyrosine kinase substrate poly-(Glu:Tyr), and the level of substrate phosphorylation was monitored over time using an ADP-production luminescence assay. This assay was used to determine the comparative \( K_m \) of each kinase for ATP and substrate, as well as \( k_{cat} \) and \( V_{max} \) values (Table 1). These data showed that the affinities for ATP and substrate were similar for each of the enzymes, with the exception of EphB2, which was lower for both. EphB2 also exhibited the fastest turnover number, which was 30% greater than that of EphB1, and >2-fold faster than EphB3 or EphB4. Although there are differences observed in the \( k_{cat} \) and \( K_m \) values between the four enzymes, when comparing their specificity constants (\( k_{cat}/K_m \)), these are all found to be within two-fold of one another. We would therefore conclude that there is no significant difference between the substrate specificities of the isolated kinase domains as characterized within this assay system using the poly-(Glu:Tyr) substrate.
Characterization of four EphB kinase domains

Figure 4  Dose-dependent inhibition of EphB enzymes using validated EphB4 kinase inhibitors

An ADP-Glo™ assay was set up, as described. Inhibition by EphB4 (closed square ■; broken line), CMPD 1 (A) and 2(B) are shown to have similar activity for EphB1 (closed circle ○; broken line) as for EphB2 (closed triangle △; broken line) and EphB3CG (open square □; unbroken line), but is less potent against EphB3 (open triangle △; unbroken line) isoform. CMPD 3 (C), however, shows similar potencies for all isoforms. The γ-axis represents luminescent response, where the minimum compound control signal was subtracted. For curve fitting, the mean max and min signals were used. Data shown are means ± S.D. of three independent experiments. (D) The structure of the EphB4 active site (2VWU), with bound CMPD1 ligand (pink), rendered by amino acid conservation across the EphB family as detailed in Supplementary Figure S1. Insert shows location of Gly699 in EphB4 (equivalent to Cys717 in EphB3) relative to the position of CMPD1 at the mouth of the active site. The dashed line shows distance in Ångströms from Cα of Gly699 to the Cδ of Ile621 which forms the roof of the opening. PyMol was used to prepare the structure Figures (http://www.pymol.org).

Ligand-binding differences

The biochemical assay was used to screen a small panel of known tyrosine kinase inhibitors (Figure 4 and Supplementary Figure S4 available at http://www.bioscirep.org/bsr/033/bsr033e040add.htm). The panel included the known EphB4 inhibitors [CMPD1 (compound 1) from the anilinoquinazoline family [34]; CMPD2, a 2, 4-bisanilinopyrimidine [35]; and CMPD3, a cyano-substituted version of CMPD2], together with a selection of clinical tyrosine kinase inhibitors. The results show a range of potencies against the EphB kinases (Table 3). Interestingly, five of the seven compounds are markedly less potent against EphB3 than the other three kinases, with two exceptions: CMPD3 and Dasatinib [36]. This observation was confirmed by ITC (isothermal titration calorimetry), where the affinity of CMPD1 for each of the four kinases was measured (Supplementary Figure S5 available at http://www.bioscirep.org/bsr/033/bsr033e040add.htm). EphB3 has a much lower affinity for CMPD1 than the other three kinases (11.5 μM for EphB3 against sub-micromolar for the others). This difference is also demonstrated by a lower thermal stabilization effect of CMPD1 on EphB3 compared with the other three kinases in DSF compound-binding experiments (Supplementary Table S3 available at http://www.bioscirep.org/bsr/033/bsr033e040add.htm).

As the binding mode of CMPD1 and CMPD2 in EphB4 has previously been determined by X-ray crystallography [34,35],...
we were able to use these structures together with a sequence alignment (Supplementary Figure S1), to look for differences between EphB3 and EphB4 in the binding region of these two compounds (Figure 4D). The most obvious difference was at Gly699 in EphB4 which is on the outer lip of the active site; this glycine is conserved in each of the EphB kinases except EphB3 where it is a cysteine (Supplementary Figure S1). As illustrated in Figure 4(D), the solubilizing group of CMPD1 extends out into the solvent channel past Gly699. The presence of a cysteine in this position as found in EphB3 is likely to result in a steric clash with the solubilizing group, the position of which is constrained by the planar hinge binding group. This is likely to account for the lower potency of CMPD1 and related compounds with similar binding modes observed against EphB3 compared with other family members. Indeed, when this cysteine (Cys717) is mutated to a glycine, EphB3 demonstrates the same compound binding profile as the other three EphB kinases (Figure 4 and Table 3). It is worth noting at this point that the C717G mutant of EphB3 also alters the catalytic profile of the enzyme to make it more similar to EphB1 or EphB2 in terms of its $k_{cat}$ and $V_{max}$ (Table 1).

Our own in-house experiences with both the EphB2 and EphB4 subfamily members had led to similar observations (Green et al., AstraZeneca, unpublished work); while both kinases could be expressed in reasonable quantities in insect-cell expression systems, difficulties arose when attempting to produce material in E. coli for heteronuclear NMR studies. EphB2 could be bacterially expressed in a soluble form when present in a catalytically repressed or auto-inhibited form, but similar constructs of EphB4 only resulted in insoluble material, albeit at high levels.

The requirement for phosphatase co-expression to obtain homogeneous samples of protein kinases from recombinant expression systems has been previously described [37], and appears to be essential for EphB2 expression in E. coli. This is in stark contrast with EphB1, EphB3 and EphB4, which are also able to auto-phosphorylate, and are therefore active within the host cell, but whose activity does not appear to compromise E. coli growth. This disparity is likely to result from differences in substrate specificity between the EphB kinases, and potentially because EphB2 phosphorylation of one or more E. coli proteins is toxic to the cells. Supplementary Figure S1 shows the substrate-binding surface of the EphB4 kinase domain and the approximate binding orientation of the optimized Eph kinase synthetic peptide substrate EPHOPT, as defined by Davis et al. [38]. Although this surface is highly conserved between the EphB kinases, there are a few residues around this surface which are different in EphB2 and may afford some degree of selectivity, including Ala700, Ala793 and Ser825 which correspond to Ser711, Gln799 and Thr831 respectively in EphB2. These differences may allow the interaction of EphB2 with a different range of substrates and could account for the recombinant expression profile that we have observed. This agrees with the observation that EphB2 has a different substrate specificity to both EphB3 and EphB4 [38]. Additional experimentation attempt to determine whether this observation has relevance in a native human cellular context may increase our understanding of the specific roles of the different EphB kinases in terms of both normal physiology and disease.

For EphB4 the observation that we obtained transformants and cell growth in the absence of PTP1B makes toxicity an unlikely explanation for its low level of soluble expression. Also, as all four sequences had been codon-optimized for efficient

### Table 3 Inhibition data for validated EphB4 and clinical tyrosine kinase inhibitors

| Inhibitor | EphB1 IC$_{50}$ | EphB2 IC$_{50}$ | EphB3 IC$_{50}$ | EphB3 C717G IC$_{50}$ | EphB4 IC$_{50}$ |
|-----------|-----------------|-----------------|-----------------|-----------------------|-----------------|
| CMPD1     | 0.091           | 0.994           | 0.088           | 0.978                 | 4.958           |
| CMPD2     | 0.021           | 0.998           | 0.016           | 0.992                 | 0.149           |
| CMPD3     | 0.023           | 0.992           | 0.021           | 0.988                 | 0.036           |
| Afatinib  | 5.443           | 0.971           | 2.488           | 0.954                 | >100            |
| Dasatinib | 0.01            | 0.999           | 0.007           | 0.993                 | 0.007           |
| Sorafenib | 1.211           | 0.986           | 0.996           | 0.987                 | 3.584           |
| Sunitinib | 5.025           | 0.992           | 2.903           | 0.954                 | 37.27           |

$R^2$ values indicate the accuracy of fit for each dose-response curve with 100% of points lying on fitted curve; IC$_{50}$ data are reported in μM. **DISCUSSION**

#### Disparities in recombinant EphB kinase expression profiles

Previous experimentation with the Eph subfamilies has given rise to numerous interesting observations regarding their catalytic activation and auto-inhibitory mechanisms [31,32]. Related to these studies, observers have commented on the phosphorylation and toxicity issues regarding the recombinant expression of both Eph and the wider RTK family [32,37]. Wiesner et al. observed that bacterial expression of EphB2 (but not EphA4) resulted in toxicity, and thus implemented an inactivating mutation of the putative catalytic base to generate recombinant kinase in E. coli [32]. Predictably, these issues were not experienced when expressing the EphB2 kinase domain in an auto-inhibited catalytically repressed Tyr604,610 to phenylalanine double mutant form [31].
transcription and translation, it would also seem unlikely that codon usage is the issue, although this cannot be ruled out. One potential explanation for this observation is lower intrinsic stability of this EphB4 construct compared with the other three proteins. The enhanced yields of all four kinases in the presence of GroES–GroEL indicates that the chaperonin complex is aiding the in vivo folding and/or solution stability of the Eph kinases and, in particular of EphB4; such effects are in line with previous claims about folding and solubilization effects of GroES–GroEL overexpression on other recombinant proteins [39].

**Intrinsic stability variation within the EphB kinase fold**

One might expect two proteins that share a 14% difference in sequence identity (41 residues out of 294) to exhibit some degree of difference in stability profile, but the ∼17°C difference observed between the melting temperatures of the isolated EphB4 and EphB1 kinase domains is dramatic. The disparity in in vitro stability is especially significant considering that these are two intracellular enzymes with very similar functions, and is highly likely to be the main contributing factor to the observed differences in their soluble expression yields from *E. coli*. It would be interesting to investigate whether these stability differences are a result of evolutionary pressure or of random substitutions that may or may not have an impact on the in vivo activity of these enzymes. Is this difference in stability functionally relevant, or is it just that the enzymes are stable enough for their role, and the differences in stability are just a result of evolved substrate or protein–protein interaction specificity? Taking into account the fact that these are isolated domains of much larger transmembrane receptor protein molecules, an interesting further study would be to examine whether the half-lives of the EphB receptors in native cells/tissues correlates with their intrinsic stability.

It is, at present, unclear whether the differences in stability and solubility have bearing on the activity profiles of the four isozymes. The two least stable enzymes, EphB3 and EphB4, do exhibit lower turnover numbers, which may relate in some way to their thermal stability or solubility. Although small variations were observed in their affinities for ATP and substrate, as well as their turnover numbers and efficiencies, we have not in this study examined in detail which residues contribute to the differences – an investigation that, although involved, might lead us to a better understanding of factors that contribute to kinase activity.

**EphB kinase compound profiling**

The small selection of known EphB4 inhibitors and clinical tyrosine kinase inhibitors used in this study highlight the similarities in compound-binding profiles of EphB family members. The high level of sequence identity shared by the EphB family within the kinase domain means that, with the exception of EphB3, it might be very difficult to find isozyme-selective ATP-competitive inhibitors of the EphB family. To obtain selective EphB1, 2 or 4 kinase inhibitors, it may be necessary to exploit differences outside of the ATP-binding region, either by picking up long-range interactions or identifying alternative pockets that also modulate activity.

Conversely, the presence of Cys717 in EphB3 is unique among the Eph kinases and may afford the opportunity to design EphB3-specific kinase inhibitors. At present it is still unclear whether specific inhibitors of EphB3 catalytic activity might be of value in the clinic, they may, however, be useful in validating the role of EphB3 in the oncological diseases in which it has been shown to be up-regulated [40–43]. Although EphB3 kinase inhibitors have previously been described [44], it is unclear whether these inhibitors are selective enough to specifically target EphB3 against other EphB family members.

The reason for the lack of selectivity of Dasatinib is most likely a combination of its high potency and lack of sensitivity of the assay, which has a tight binding limit of approximately 25 nM. It is thought that the cyano substitution of CMPD3 may increase the potency against EphB3, owing to a specific interaction of the cyano moiety with Cys717, or a reduction in steric clash compared with the morpholine of CMPD2. In terms of its native biology, Cys717 may also have some influence on the substrate-binding specificity of EphB3, and is likely to have some in vivo significance in terms of regulation of activity.

**Conclusions**

To conclude, the data we present highlight some dramatic and intriguing differences between members of this closely related family of protein kinases in terms of their physiochemical properties. It would appear from our findings that EphB3 is an outlier in terms of both its intrinsic folding mechanism and ligand-binding properties and that EphB2 may have a subtly different substrate-binding profile, which could have a biological significance. It is hoped that these observations will enable a greater biological understanding of this important class of receptors by facilitating production of recombinant protein tools, as well as potent and selective small molecules to aid mechanistic studies.

**AUTHOR CONTRIBUTION**

Ross Overman performed the molecular biology, protein expression and purification, biophysical analysis, enzyme kinetics, protein crystalization and drafted the paper. Judit Debreczeni co-wrote the crystallography elements of the paper. Caroline Truman helped with the enzyme kinetics and performed the compound screening and analysis, and co-wrote the compound screening parts of the paper. Mark McAlister and Teresa Attwood supervised the project, made substantial contributions to the conception and design of the experiments, interpretation of data, and helped with revision of the paper for intellectual content. All authors read and approved the final paper.

**ACKNOWLEDGEMENTS**

We thank Geoff Holdgate and Dr Gareth Davies for their assistance with CD and ITC analysis and Dr Julie Tucker for help with crystalization screening.
REFERENCES

1 Manning, G., Whyte, D. B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298, 1912–1934

2 Gale, N. W., Holland, S. J., Valenzuela, D. M., Flenniken, A., Pan, L., Ryan, T. E., Henkemeyer, M., Strebhardt, K., Hirai, H., Wilkinson, D. G. et al. (1996) Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neurogen 17, 9–19

3 Pasquale, E. B. (2005) Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 6, 462–475

4 Labrador, J. P., Brambilla, R. and Klein, R. (1997) The N-terminal globular domain of eph receptors is sufficient for ligand binding and receptor signaling. EMBO J. 16, 3869–3879

5 Pasquale, E. B. (2008) Eph-ephrin bidirectional signaling in physiology and disease. Cell 133, 38–52

6 Meyer, S., Hafner, C., Guba, M., Flegel, S., Geissler, E. K., Becker, B., Koehl, G. E., Orso, E., Landthaler, M. and Vogt, T. (2005) Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int. J. Oncol. 27, 1197–1206

7 Cooke, J., Moens, C., Roth, L., Durbin, L., Shiomi, K., Brennan, C., Kimmel, C., Wilson, S. and Holder, N. (2001) Eph signaling functions downstream of Val to regulate cell sorting and boundary formation in the caudal hindbrain. Development 128, 571–580

8 Poliakov, A., Cotrina, M. and Wilkinson, D. G. (2004) Diverse roles of eph receptors and ephrins in the regulation of cell migration and tissue assembly. Dev. Cell 7, 465–480

9 Gerety, S. S. and Anderson, D. J. (2002) Cardiovascular ephrinB2 function is essential for embryonic angiogenesis. Development 129, 1397–1410

10 Henkemeyer, M., Oriol, D., Henderson, J. T., Saxton, T. M., Rod, J., Pawson, T. and Klein, R. (1996) Nuk controls pathfinding of commissural axons in the mammalian central nervous system. Cell 86, 35–46

11 Flanagan, J. G. and Vanderhaeghen, P. (1998) The ephrins and eph receptors in neural development. Annu. Rev. Neurosci. 21, 309–345

12 Pasquale, E. B. (2010) Eph receptors and ephrins in cancer: bidirectional signaling and beyond. Nat. Rev. Cancer 10, 165–180

13 Huusko, P., Ponciano-Jackson, D., Wolf, M., Kiefer, J. A., Azorsa, D. O., Tuzmen, S., Weaver, D., Robbins, C., Moses, T. and Holder, N. (2004) Nonsense-mediated decay microarray analysis identifies mutations of EphB2 in human prostate cancer. Nat. Genet. 36, 979–983

14 Alazzouzi, H., Davalos, V., Kokko, A., Domingo, E., Woolner, S. M., Wilson, A. J., Konrad, L., Laiho, P., Espan, I., Armengol, M. et al. (2005) Mechanisms of inactivation of the receptor tyrosine kinase EphB2 in colorectal cancers. Cancer Res. 65, 10170–10173

15 Genander, M., Hafmond, M. M., Xu, N., Eriksson, M., Yu, Z., Qiu, Z., Martling, A., Greicius, G., Thakar, S., Catchpole, T. et al. (2009) Dissociation of EphB2 signaling pathways mediating progenitor cell proliferation and tumor suppression. Cell 139, 679–692

16 Kumar, S. R., Masood, R., Spannuth, W. A., Singh, J., Schenert, J., Kleiber, G., Jennings, N., Deavers, M., Krasnoperov, V., Dubleau, L. et al. (2007) The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br. J. Cancer 96, 1083–1091

17 Dopoulos, H., Mateo-Lozano, S., Mazzolini, R., Rodrigues, P., Lagares-Tena, L., Ceron, J., Romero, J., Esteves, M., Landolfi, S., Hernández-Losa, J. et al. (2009) The receptor tyrosine kinase EphB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Res. 69, 7430–7438

18 Chiou, S., Chang, K., Ting, C., Shen, H., Li, H. and Hsieh, F. (2009) Overexpression of EphB3 enhances cell-cell contacts and suppresses tumor growth in HT-29 human colon cancer cells. Carcinogenesis 30, 1475–1486

19 Li, G., Xu, G., Hao, Z., Zhao, J., Xu, J., Sun, Z., Deng, Y., Shi, S., Feng, Y., Zhu, Y. et al. (2012) EphB3 suppresses non-small-cell lung cancer metastasis via a PP2A/RACK1/Akt signalling complex. Nat. Commun. 3, 667

20 Astin, J. W., Batson, J., Kadir, S., Charlet, J., Persad, R. A., Gillatt, D., Oxley, J. D. and Nobes, C. D. (2010) Competition amongst eph receptors regulates contact inhibition of locomotion and invasiveness in prostate cancer cells. Nat. Cell. Biol. 12, 1194–1204

21 Sheng, Z., Wang, J., Dong, Y., Ma, H., Zhou, H., Sugimura, H., Lu, G. and Zhou, X. (2008) EphB1 is underexpressed in poorly differentiated colorectal cancers. Pathobiology 75, 274–280

22 Wang, J., Dong, Y., Sheng, Z., Ma, H., Li, G., Wang, X., Lu, G., Sugimura, H., Jin, J. and Zhou, X. (2007) Loss of expression of EphB1 protein in gastric carcinoma associated with invasion and metastasis, Oncology 73, 238–245

23 Liu, S., Liu, W., Liu, Y., Dong, H., Henkemeyer, M., Xiong, L. and Song, X. (2011) Blocking EphB1 receptor forward signaling in spinal cord relieves bone cancer pain and rescues analgesic effect of morphine treatment in rodents. Cancer Res. 71, 4392–4402

24 Xi, H., Wu, X., Wei, B. and Chen, L. (2012) Eph receptors and ephrins as targets for cancer therapy. J. Cell. Mol. Med. 16, 2894–2909

25 Freywald, A.,Sharfe, N. and Roifman, C. M. (2002) The kinase-null EphB6 receptor undergoes transphosphorylation in a complex with EphB1. J. Biol. Chem. 277, 3823–3828

26 Tobbell, D. A., Middleton, B. J., Raines, S., Needham, M. R., Taylor, I. W., Beveridge, J. Y. and Abbott, W. M. (2002) Identification of in vitro folding conditions for procathepsin S and cathepsin S using fractional factorial screens. Protein Expr. Purif. 24, 242–254

27 Consalvi, V., Chiariuluce, L., Giangiacomo, L., Scandurra, R., Christova, M., Karshikoff, A., Knapp, S. and Ladenstein, R. (2000) Thermal unfolding and conformational stability of the recombinant domain II of glutamate dehydrogenase from the hyperthermophile thermotoga maritima. Protein Eng. 13, 501–507

28 Van Nuland, N., Niesing, R. and Scheek, R. M., Robillard, G. T. and Dobson, C. M. (1998) Slow cooperative folding of a small globular protein HPr. Biochemistry 37, 622–637

29 Fan, Y., Zhou, J., Tsou, C. and Kihara, H. (1998) Unfolding and refolding of dimeric creatine kinase equilibrium and kinetic studies. Protein Sci. 7, 2631–2641

30 Bardelle, C., Coleman, T., Cross, D., Davenport, S., Kettle, J. G., Ko, E. J., Leach, A. G., Mortlock, A., Read, J., Roberts, N. J. et al. (2008) Inhibitors of the tyrosine kinase EphB4. part 2: structure-based discovery and optimisation of 3,5-bis substituted anilinopyrimidines. Bioorg. Med. Chem. Lett. 18, 5717–5721

31 Wybenga-Groot, L. E., Baskin, B., Ong, S. H., Tong, J., Pawson, T. and Schecki, F. (2001) Structural basis for autoinhibition of the EphB2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 106, 745–757

32 Wiesner, S., Wybenga-Groot, L. E., Warner, N., Lin, H., Pawson, T. and Schecki, F. (2006) A change in conformational dynamics underlies the activation of eph receptor tyrosine kinases. EMBO J. 25, 4686–4696

33 Niesen, F. H., Berglund, H. and Vedadi, M. (2007) The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2, 2212–2221
Characterization of four EphB kinase domains

34 Bardelle, C., Cross, D., Davenport, S., Kettle, J. G., Ko, E. J., Leach, A. G., Mortlock, A., Read, J., Roberts, N. J., Robins, P. et al. (2008) Inhibitors of the tyrosine kinase EphB4. part 1: structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. Bioorg Med Chem Lett 18, 2776–2780

35 Barlaam, B., Ducray, R., Bremp, C. L. d., Pié, P., Bardelle, C., Brooks, N., Coleman, T., Cross, D., Kettle, J. G. and Read, J. (2011) Inhibitors of the tyrosine kinase EphB4. part 4: Discovery and optimization of a benzylic alcohol series. Bioorg. Med. Chem. Lett. 21, 2207–2211

36 Lombardo, L. J., Lee, F. Y., Chen, P., Norris, D., Barrish, J. C., Behnia, K., Castaneda, S., Cornelius, L. A. M., Das, J., Doweyko, A. M. et al. (2004) Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658–6661

37 Wang, W., Marimuthu, A., Tsai, J., Kumar, A., Krupka, H. i., Zhang, C., Powell, B., Suzuki, Y., Nguyen, H., Tabrizi, M. et al. (2006) Structural characterization of autoinhibited c-met kinase produced by coexpression in bacteria with phosphatase. Proc. Natl. Acad. Sci. U.S.A. 103, 3563–3568

38 Davis, T. L., Walker, J. R., Allali-Hassani, A., Parker, S. A., Turk, B. E. and Dhe-Paganon, S. (2009) Structural recognition of an optimized substrate for the ephrin family of receptor tyrosine kinases. FEBS J. 276, 4395–4404

39 Nishihara, K., Kanemori, M., Kitagawa, M., Yanagi, H. and Yura, T. (1998) Chaperone coexpression plasmids: differential and synergistic roles of DnaK–DnaJ–GroES and GroEL–GroES in assisting folding of an allergen of Japanese cedar pollen, Cryj2, in Escherichia coli. Appl. Environ. Microbiol. 64, 1694–1699

40 Farivar, R. S., Gardner-Thorpe, J., Ito, H., Arshad, H., Zinner, M. J., Ashley, S. W. and Whang, E. E. (2003) The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines. J. Surg. Res. 115, 219–225

41 Berardi, A. C., Marsilio, S., Rofani, C., Salvucci, O., Altavista, P., Perla, F. M., Diomedi-Camassei, F., Uccini, S., Kokai, G., Landuzzi, L. et al. (2008) Up-regulation of EphB and ephrin-B expression in rhabdomyosarcoma. Anticancer Res. 28, 763–769

42 Kang, J. U., Koo, S. H., Kwon, K. C., Park, J. W. and Kim, J. M. (2009) Identification of novel candidate target genes, including EPB3, MAS1 and SST at 3q26.2-q29 in squamous cell carcinoma of the lung. BMC Cancer 9, 237

43 Ji, X. D., Li, G., Feng, Y. X., Zhao, J. S., Li, J. J., Sun, Z. J., Shi, S., Deng, Y. Z., Xue, J. F., Zhu, Y. Q. et al. (2011) EphB3 is overexpressed in non-small-cell lung cancer and promotes tumor metastasis by enhancing cell survival and migration. Cancer Res. 71, 1156–1166

44 Qiao, L., Choi, S., Case, A., Gainer, T. G., Seyb, K., Glicksman, M. A., Lo, D. C., Stein, R. L. and Cuny, G. D. (2009) Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioorg. Med. Chem. Lett. 19, 6122–6126

Received 22 February 2013/4 April 2013; accepted 23 April 2013

Published as Immediate Publication 29 April 2013, doi 10.1042/BSR20130028
SUPPLEMENTARY DATA

Biochemical and biophysical characterization of four EphB kinase domains reveals contrasting thermodynamic, kinetic and inhibition profiles

Ross C. OVERMAN*,1, Judit E. DEBRECZENI*, Caroline M. TRUMAN*, Mark S. McALISTER* and Teresa K. ATTWOOD†

*AstraZeneca PLC, Alderley Park, Cheshire, SK10 4TG, U.K., and †Faculty of Life Sciences and School of Computer Science, The University of Manchester, Oxford Road, Manchester M13 9PL, U.K.

EphB kinase sequence similarity

The EphB sub-family of RTKs share high sequence identity at the protein level throughout the entire receptor length (average 64%), with very high similarity in the catalytic domain itself, as defined by UniprotKB (average 88%) (Supplementary Figure S1 and Table S1). The exception to this is EphB6, a catalytically inactive protein kinase that only shares an average of 47% identity with the other four receptors across the whole receptor, and 61% within the catalytic domain; therefore, EphB6 was omitted from this study. Within these domain boundaries, the four kinases share sequence identity ranging from 83% (EphB2/EphB4) to 88% (EphB1/EphB3). Supplementary Figure S1(B) is a ribbon and surface representation of the EphB4 structure (2VWU), showing the degree of sequence conservation across EphB1-4 to exemplify which areas of the four kinase domains are most divergent.

1 To whom correspondence should be addressed (email: ross.overman@astrazeneca.com).
Figure S1  Sequence and structural similarity of the EphB kinase domains

(A) Sequence alignment of the four human EphB protein kinase domains used in this study, demonstrating their high level of sequence identity. Residue numbering is taken from the human sequences as described in UniProtKB/Swiss-Prot: EphB1: P54762, EphB2: P29323, EphB3: P54753, EphB4: P54760. Residues are coloured by amino acid conservation scoring generated by PRALINE [1]: dark blue = strictly conserved, through to red = non-conserved. The open and closed arrows refer to the start and end of the electron density in the EphB4 kinase domain structure used below (2VWU). The closed triangle (▲) corresponds to the position of Cys717 in EphB3 (Gly699 in EphB4). The alignment was generated using ClustalW [2].

(B) The structure of EphB4 (2VWU), with bound CMPD1 (pink), rendered by amino acid conservation as above. (C) The approximate position of the EPHOPT peptide [3] shown on the EphB4 substrate-binding surface, labelled residues are conserved in EphB1, EphB3 and EphB4 but not in EphB2. PyMol was used to prepare the structure Figures (http://www.pymol.org).
Figure S2  Secondary structure profiles of EphB kinases determined using CD spectroscopy
A molar concentration adjusted 260–195 nm CD wavelength scan of each of the four EphB kinase domains to demonstrate their secondary structure profiles, n = 3. Measurements were conducted as described in the Materials and methods section. All four proteins demonstrate highly similar secondary structure profiles as would be predicted from their sequence similarity.
**Figure S3 Differential scanning fluorimetry (DSF) thermal unfolding of EphB kinases**

(A) Representative unfolding transitions obtained for each of the four kinases from DSF thermal denaturation experiments using a Bio-Rad iCycler iQ real time PCR instrument. (B) Thermal unfolding transitions of EphB4 in the presence of an increasing concentration of CMPD 1 to demonstrate ligand stabilization. The final reaction volume was 25 μl containing 12 μM protein and 1/1000 Sypro Orange dye (Molecular Probes) in 50 mM sodium phosphate, pH 7.4 and 1 mM TCEP. Unfolding reactions were performed in triplicate within 96-well iCycler iQ PCR plates covered with optical tape (Bio-Rad). The heating block of the machine was programmed to ramp from 20°C to 90°C in 0.2°C increments at a rate of 1°C per min. Fluorescence intensity of the dye was monitored using the integrated charge-coupled device CCD camera at 575 nm. The primary data points (relative fluorescence intensity against temperature) were extracted and the unfolding curves were fitted to equation (1) [4] using Prism software (GraphPad Software, Inc.), to obtain thermodynamic parameters shown in Table S3. CMPD 1 was included over a concentration range of 5–100 μM at a final DMSO concentration of 2% DMSO.
Figure S4  Dose-dependent inhibition of EphB enzymes using clinical kinase inhibitors
An ADP-Glo™ assay was set up as described. The potencies of Dasatinib (A) are similar for all isoforms; EphB1 (closed circle ●; broken line) as for EphB2 (solid triangle ▲; broken line), EphB3 (open triangle △; unbroken line), EphB3CG (open square □; unbroken line) and EphB4 (closed square ■; broken line) isoform. However, Sorafenib (B), Sunitinib (C) and Afatinib (D) show similar potencies for isoforms EphB1, 2, 4 and 3CG mutation, but are less potent for wild-type EphB3 isoform. The y-axis represents luminescent response, where the min compound control signal was subtracted. For curve fitting, the mean max and min signals were used. Data shown are means ± S.D. of three independent experiments.
Table S1 Sequence conservation between the EphB kinases
A similarity table generated from an alignment of EphB kinases family members using the ClustalW algorithm within AlignX (Vector NTI Advance, Invitrogen Corp.); values in brackets are for the full-length receptors. The sequences used are those described in the following UniProtKB/Swiss-Prot entries: EphB1: P54762, EphB2: P29323, EphB3: P54753, EphB4: P54760.

| Enzyme | EphB1 | EphB2 | EphB3 | EphB4 |
|--------|-------|-------|-------|-------|
| EphB1  | –     | 89 (73)| 88 (71)| 86 (57)|
| EphB2  | –     | –     | 88 (70)| 83 (55)|
| EphB3  | –     | –     | –     | 86 (59)|
| EphB4  | –     | –     | –     | –     |

Table S2 Recombinant expression level and phosphorylation status of the EphB kinases
Approximate soluble, purifiable expression levels of the EphB kinase domains in the four different E. coli strains (estimated from SDS/PAGE gels using a titration of purified insect-expressed EphB4 kinase of known concentration), and their phosphorylation status as determined by LC–MS. Expression strains: Strain 1: host strain [BL21 Star (DE3)]; Strain 2: host strain plus pGro7 (GroEL/GroES); Strain 3: host strain plus pRSP-PTP1B; Strain 4: host strain plus pRSP-PTP1B and pGro7.

| Enzyme | Strain 1 | Strain 2 | Strain 3 | Strain 4 |
|--------|----------|----------|----------|----------|
| EphB1  | 6 [+3, +4, +5, +6] | 7 [+3, +4, +5, +6] | 4 [0] | 6 [0] |
| EphB2  | N/D [N/D] | N/D [N/D] | 15 [0] | 25 [0] |
| EphB3  | 3 [+2, +3, +4] | 5 [+2, +3, +4] | 5 [0] | 7 [0] |
| EphB4  | 0.1 [N/D] | 1 [+2, +3, +4, +5] | 0.1 [N/D] | 1 [0] |

Figure S5  Isothermal titration calorimetry (ITC) measurements using CMPD 1
The functional enzyme concentration and CMPD 1 affinity for each kinase was determined by ITC using a MicroCal ITC200 microcalorimeter. All proteins were rapidly defrosted and extensively dialysed at 4 °C into 50 mM HEPES (pH7.4), 25 mM NaCl, 20 mM MgCl₂ and 0.1 mM TCEP. 5 % DMSO was added to the protein solution to give a final protein concentration in the cell of 23.75 μM. CMPD 1 was present in the syringe at 250 μM in 50 mM HEPES (pH 7.4), 25 mM NaCl, 20 mM MgCl₂, 0.1 mM TCEP and 5 % DMSO. Run parameters were as follows: total no. of injections: 20 × 2 μl, injection duration: 4 s, injection spacing: 180 s, filter period: 5 s, cell temperature: 25 °C, reference power: 6 μa/s, initial delay: 60 s, stirring speed 1000 rev./min. Titration data were fitted to a one site model using Origin software (OriginLab) with a heat of dilution subtraction (heat of dilution experiments were carried out for each construct as above using DMSO in the absence of compound). Final graphs showing heats from each injection against the ratio of ligand and binding partner (kinase) in the cell (top panel) and the binding isotherm/integrated heats (bottom panel). (A) EphB1, (B) EphB2, (C) EphB3 and (D) EphB4.
Table S3 Thermodynamic parameters calculated from DSF unfolding of EphB kinases
The melting temperature and van’t Hoff enthalpy of unfolding of non-phosphorylated Eph samples and hen egg white lysozyme control were calculated from triplicate unfolding experiments. The rank order of melting temperature ($T_m$) agrees between DSF and CD; however, using DSF, they were calculated to be between 2.5 and 4.0°C lower (Table 1, main paper), which could be due to a number of factors, including ramp rates, dwell times and thermal energy transfer rates. CMPD1 was added to the protein samples at a range of concentrations in the DSF unfolding experiments. A substantial stabilization effect (+4.5 to +8.4°C) was observed for all four proteins in the presence of 100 μM CMPD1, demonstrating that this method could be used to find ligands of EphB kinases. n>3 for all measurements, errors shown are calculated standard errors.

| DSF thermodynamic parameters | Enzyme | $T_m$ (°C) | $\Delta U_{H}^{\text{fnoC}}$ (kJ/mol) | $\Delta T_m$ (°C) $+100 \mu M$ CMPD1 |
|------------------------------|--------|------------|-------------------------------------|--------------------------------------|
| EphB1                        | 57.2 ± 0.1 | 132.1 ± 2.2 | +6.1 ± 0.1                           |
| EphB2                        | 50.7 ± 0.1 | 97.0 ± 1.1  | +8.2 ± 0.1                           |
| EphB3                        | 41.0 ± 0.2 | 88.5 ± 2.8  | +4.5 ± 0.2                           |
| EphB4                        | 38.8 ± 0.1 | 109.3 ± 1.1 | +8.4 ± 0.1                           |

Table S4 Thermodynamic parameters obtained from ITC titration experiments of EphB enzymes with CMPD1
Errors shown are calculated standard errors.

| ITC Data CMPD1 | Enzyme | $N$ | $K_d$ (μM) | $\Delta H$ (kJ/M) |
|----------------|--------|-----|------------|-------------------|
| EphB1          | 0.993 ± 0.003 | 0.051 ± 0.006 | -67.28 ± 0.88   |
| EphB2          | 0.954 ± 0.005 | 0.131 ± 0.016 | -44.39 ± 0.74   |
| EphB3          | 1.002 ± 0.076 | 11.47 ± 2.83  | -51.71 ± 13.30  |
| EphB4          | 0.921 ± 0.006 | 0.065 ± 0.015 | -57.66 ± 1.50   |
| EphB3 C717G    | 1.060 ± 0.017 | 0.301 ± 0.081 | -51.09 ± 2.75   |

REFERENCES

1 Heringa, J. (2002) Local weighting schemes for protein multiple sequence alignment. Comput. Chem. 26, 459–477
2 Larkin, M. A., Blackshields, G., Brown, N. R, Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R. et al. (2007) Clustal W and clustal X version 2.0. Bioinformatics 23, 2947–2948
3 Davis, T. L., Walker, J. R., Allali-Hassani, A., Parker, S. A., Turk, B. E. and Dhe-Paganon, S. (2009) Structural recognition of an optimized substrate for the ephrin family of receptor tyrosine kinases. FEBS J. 276, 4395–4404
4 Consalvi, V., Chiaraaluce, R., Giangiacomo, L., Scandurra, R., Christova, P., Karshikoff, A., Knapp, S. and Ladenstein, R. (2000) Thermal unfolding and conformational stability of the recombinant domain II of glutamate dehydrogenase from the hyperthermophile thermotoga maritima. Protein Eng. 13, 501-507

Received 22 February 2013/4 April 2013; accepted 23 April 2013
Published as Immediate Publication 29 April 2013, doi 10.1042/BSR20130028